MVMaria A. Vicente

Maria A. Vicente

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria A. Vicente has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Alline Cristina Campos

    Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; Center for Cannabinoid Research, School of Medicine of Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

    2 shared publications
  • Pedro Henrique Cassaro Lirio

    Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil; Center for Cannabinoid Research, School of Medicine of Ribeirao Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

    2 shared publications
  • Bruno Lemes Marques

    Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, 3900, Bandeirantes Avenue, Monte Alegre, Ribeirão Preto 14049-900, SP, Brazil

    1 shared publication
  • Carlos A. Sorgi

    Department of Chemistry- School of Philosophy, Science and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

    1 shared publication
  • Eduardo J. Fusse

    Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil

    1 shared publication
  • Feng Guo

    Department of Intelligent Systems Engineering, Indiana University Bloomington, IN, 47405, United States

    1 shared publication

Latest Publications

  • Cannabidiol reduces the latency for the behavioral effect of escitalopram in chronically stressed male mice: involvement of NAPE-PLD expressed in parvalbumin-positive interneurons and the prefrontal cortex

    by FrancieleF. Scarante, Vinícius D. Lopes, Eduardo J. Fusse, Maria A. Vicente, Gabriel H.D. de Abreu, Viviani Nardini, Carlos A. Sorgi, Pedro H.C. Lirio, Feng Guo, Hui-Chen Lu, et al.


  • Open Access

    Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review

    by Bruno L. Marques, Pedro H. C. Lirio, Maria A. Vicente, Paula Unzueta-Larrinaga, Leyre Urigüen, Alline C. Campos

    Background and Objectives: Neuropsychiatric disorders pose a major global health challenge, marked by high prevalence, limited diagnostic precision, and suboptimal therapeutic outcomes. Current diagnoses remain primarily clinical, lacking objective biomarkers, while many patients experience poor remission rates and frequent relapse. The endocannabinoid system (ECS), a central regulator of synaptic plasticity, neuroinflammation, and stress responses, is increasingly implicated in depression, anxiety, schizophrenia, and neurodegenerative diseases. In parallel, extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication and promising biomarker sources, as they reflect the physiological or pathological status of their cells of origin. This review examines the hypothesis that interactions between ECS signaling and EV-mediated communication form a convergent pathway shaping vulnerability and resilience in neuropsychiatric disorders, with potential implications for biomarker identification and therapeutic innovation. Methods: This hypothesis-driven review was developed using a narrative approach, focusing on the interface between cannabinoids and EVs in neuropsychiatric conditions. Relevant publications were identified through PubMed, Scopus, and Web of Science searches up to September 2025. Results: Emerging evidence indicates a bidirectional relationship between ECS activity and EV biology: endocannabinoids can be loaded into EVs to facilitate intercellular signaling, while phytocannabinoids such as THC and CBD can alter EV release and cargo composition. Conclusions: We propose a hypothesis-driven framework in which the possible interplay between cannabinoids and EVs may stimulate new research and support the development of biomarker-guided, personalized therapeutic strategies for neuropsychiatric disorders.